A phase II clinical trial of drug withdrawal in women with progressive breast cancer while on aromatase inhibitor therapy.

Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08

European Journal of Cancer ◽

10.1016/j.ejca.2015.03.016 ◽

2015 ◽

Vol 51 (10) ◽

pp. 1212-1220 ◽

Cited By ~ 22

Author(s):

Khalil Zaman ◽

Ralph Winterhalder ◽

Christoph Mamot ◽

Ursula Hasler-Strub ◽

Christoph Rochlitz ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Phase Ii Trial ◽

Inhibitor Therapy ◽

Double Blind ◽

Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy

British Journal of Cancer ◽

10.1038/bjc.2014.502 ◽

2014 ◽

Vol 111 (11) ◽

pp. 2046-2050 ◽

Cited By ~ 5

Author(s):

Y Chavarri-Guerra ◽

M J Higgins ◽

J Szymonifka ◽

T Cigler ◽

P Liedke ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Aromatase Inhibitor ◽

Drug Withdrawal ◽

Metastatic Breast ◽

Inhibitor Therapy ◽

Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial

Journal of the American College of Surgeons ◽

10.1016/j.jamcollsurg.2009.01.035 ◽

2009 ◽

Vol 208 (5) ◽

pp. 906-914 ◽

Cited By ~ 53

Author(s):

John A. Olson ◽

G. Thomas Budd ◽

Lisa A. Carey ◽

Lyndsay A. Harris ◽

Laura J. Esserman ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Cancer Patients ◽

Phase Ii ◽

Surgical Outcomes ◽

Phase Ii Trial ◽

Inhibitor Therapy ◽

Breast Cancer Patients ◽

Multicenter Phase

Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.1052 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 1052-1052 ◽

Cited By ~ 12

Author(s):

A. M. Wardley ◽

R. Stein ◽

J. McCaffrey ◽

J. Crown ◽

Z. Malik ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Histone Deacetylase ◽

Phase Ii ◽

Histone Deacetylase Inhibitor ◽

Inhibitor Therapy ◽

Deacetylase Inhibitor ◽

Class 1

Abstract SY10-01: Whole genome sequencing and analysis in a clinical trial setting: Aromatase inhibitor therapy in breast cancer

10.1158/1538-7445.am2011-sy10-01 ◽

2011 ◽

Author(s):

Elaine Mardis

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Aromatase Inhibitor ◽

Whole Genome Sequencing ◽

Genome Sequencing ◽

Inhibitor Therapy ◽

Whole Genome ◽

Clinical Trial Setting ◽

Trial Setting

Adjuvant aromatase inhibitor therapy for breast cancer

PsycEXTRA Dataset ◽

10.1037/e459052008-007 ◽

2008 ◽

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Inhibitor Therapy ◽

Neuropsychological Functioning in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitor Therapy

PsycEXTRA Dataset ◽

10.1037/e684272011-001 ◽

2011 ◽

Author(s):

Jacqueline R. Weaver ◽

Shauna M. Stark ◽

Karineh T. Shaverdi ◽

Stacie Jeter ◽

Jane Zorzi ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Cancer Patients ◽

Neuropsychological Functioning ◽

Inhibitor Therapy ◽

Breast Cancer Patients ◽

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Case Medical Research ◽

10.31525/ct1-nct04256941 ◽

2020 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Aromatase Inhibitor ◽

Metastatic Breast ◽

Inhibitor Therapy ◽

Activating Mutation

Faculty Opinions recommendation of A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727678658.793546414 ◽

2018 ◽

Author(s):

Jay H Ryu

Keyword(s):

Clinical Trial ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Phase Ii ◽

Phase Ii Clinical Trial

Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: Rationale and design of a randomized controlled trial

Contemporary Clinical Trials ◽

10.1016/j.cct.2011.04.012 ◽

2011 ◽

Vol 32 (5) ◽

pp. 704-709 ◽

Cited By ~ 5

Author(s):

Sharon Kilbreath ◽

Kathryn M. Refshauge ◽

Jane Beith ◽

Leigh Ward ◽

Kate Sawkins ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Controlled Trial ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Early Breast Cancer ◽

Controlled Trial ◽

Inhibitor Therapy ◽

Randomized Controlled ◽

Prevention Of Osteoporosis